

### Claims

1. Use of rotigotine, its salts and prodrugs for the preparation of a medicament for the prevention and/or treatment of Parkinson's plus syndrome.
2. Use according to claim 1, wherein the Parkinson's plus syndrome is selected from the following group: multiple system atrophies, progressive supranuclear palsy, corticobasal degeneration and diffuse dementia with Lewy bodies.
3. Use according to one of the preceding claims, wherein the Parkinson's plus syndrome is characterised by the failure to respond to L-dopa.
4. Use according to one of the preceding claims, wherein the medicament is designed for parenteral, transdermal or transmucosal administration.
5. Use according to one of the preceding claims, wherein the rotigotine is administered in a dose of 0.05-50 mg a day.
6. Use according to one of the preceding claims, wherein the prodrug is an ether, ester, thiocarbonyl ester, carbamate, thiocarbamate, carbonate, acetal, ketal, acyloxy alkyl ether, oxythiocarbonyl ester, phosphate, phosphonate, sulfate, sulfonate or silylether of the phenolic hydroxy group of rotigotine.
7. Use according to claim 6, wherein the prodrug is an alkyl carbonyl ester with up to 6 carbon atoms.